Evidence map›Paper›PMID 29116514›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens.

Yang Su, Scott Bidlingmaier, Nam-Kyung Lee, Bin Liu

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  4. CD46 targetedJournal of experimental & clinical cancer research : CR · 2023
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yang SuDepartment of Anesthesia, UCSF Helen Diller Family Comprehensive Cancer Center, 1001 Potrero Ave., 1305, San Francisco, CA, 94110, USA.
Scott BidlingmaierDepartment of Anesthesia, UCSF Helen Diller Family Comprehensive Cancer Center, 1001 Potrero Ave., 1305, San Francisco, CA, 94110, USA.
Nam-Kyung LeeDepartment of Anesthesia, UCSF Helen Diller Family Comprehensive Cancer Center, 1001 Potrero Ave., 1305, San Francisco, CA, 94110, USA.
Bin LiuDepartment of Anesthesia, UCSF Helen Diller Family Comprehensive Cancer Center, 1001 Potrero Ave., 1305, San Francisco, CA, 94110, USA. bin.liu@ucsf.edu.
UCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Mapping a clinically significant internalizing tumor epitope space.R01CA118919 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2006 to 2013
$2.5M
Internalizing human antibody-targeted nanosized siRNA therapeuticsR01CA171315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2012 to 2016
$1.6M
Identifying antigens bound by novel scFvs targeting all subtypes of mesotheliomaR01CA129491 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2010 to 2013
$1.2M
NCI NIH HHS R01 CA118919NCI NIH HHS R01 CA129491NCI NIH HHS R01 CA171315
6 · The paper itself

Abstract

A functional approach to generate tumor-targeting human monoclonal antibodies is through selection of phage antibody display libraries directly on tumor cells. Although technically convenient, the use of cancer cell lines for the selection has limitations as those cell lines often undergo genetic and epigenetic changes during prolonged in vitro culture and alter their cell surface antigen expression profile. The key is to develop a technology that allows selection of phage antibody display libraries on tumor cells in situ residing in their natural tissue microenvironment. Laser capture microdissection (LCM) permits the precise procurement of tumor cells from human cancer patient tissue sections. Here, we describe a LCM-based method for selecting phage antibodies against tumor cells in situ using both fresh frozen and paraffin-embedded tissues. To restrict the selection to antibodies that bind internalizing epitopes, the method utilizes a polyclonal phage population pre-enriched for internalizing phage antibodies. The ability to recognize tumor cells in situ residing in their natural tissue microenvironment and to deliver payload intracellularly makes these LCM-selected antibodies attractive candidates for the development of targeted cancer therapeutics.

Indexed as

Antibodies, NeoplasmGene LibraryLaser Capture MicrodissectionPeptide LibrarySingle-Chain AntibodiesAntigens, NeoplasmCloning, MolecularHumansNeoplasmsAntibodies, NeoplasmAntigens, NeoplasmPeptide LibrarySingle-Chain AntibodiesHuman cancer specimenInternalizing human monoclonal antibodyIntracellular payload deliveryLaser capture microdissectionMacropinocytosisNatural cell surface epitopePhage antibody librarySolid tumorTargeted therapyTissue microenvironment

Identifiers

PMID29116514
PMCPMC8685230
OpenAlexW2767791453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.